Mereo BioPharma (MREO) Operating Leases (2018 - 2024)

Mereo BioPharma (MREO) has reported Operating Leases for 7 consecutive years, with $187000.0 the latest figure, recorded in Q4 2024.

• On a quarterly basis, Operating Leases fell 79.36% year-over-year to $187000.0 in Q4 2024; TTM through Dec 2024 was $187000.0, a 79.36% decrease from a year earlier, with the FY2024 full-year figure at $187000.0, down 79.36% from the prior year.
• Operating Leases was $187000.0 for Q4 2024 at Mereo BioPharma, down from $394000.0 in the prior quarter.
• Over five years, Operating Leases peaked at $13.9 million in Q2 2020 and troughed at $187000.0 in Q4 2024.
• A 5-year average of $2.4 million and a median of $1.4 million in 2022 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases sank 87.24% in 2020 and surged 54.63% in 2021, its largest moves.
• Over 5 years, Operating Leases stood at $1.5 million in 2020, then surged by 54.63% to $2.4 million in 2021, then sank by 39.38% to $1.4 million in 2022, then tumbled by 36.79% to $906000.0 in 2023, then tumbled by 79.36% to $187000.0 in 2024.
• The last three Operating Leases figures came in at $187000.0 (Q4 2024), $394000.0 (Q3 2024), and $552000.0 (Q2 2024), per Business Quant data.